glutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1311 | 56-85-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 10, 2004 | FDA | EMMAUS MEDCL |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisis | 73.52 | 22.39 | 18 | 1177 | 5985 | 63481842 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisis | 149.04 | 29.71 | 30 | 649 | 4023 | 34952229 |
| Tendon calcification | 52.38 | 29.71 | 7 | 672 | 68 | 34956184 |
| Acute chest syndrome | 48.03 | 29.71 | 9 | 670 | 818 | 34955434 |
| Blood parathyroid hormone increased | 31.37 | 29.71 | 7 | 672 | 1507 | 34954745 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisis | 182.65 | 21.43 | 40 | 1526 | 7882 | 79734940 |
| Tendon calcification | 47.16 | 21.43 | 7 | 1559 | 149 | 79742673 |
| Acute chest syndrome | 42.20 | 21.43 | 9 | 1557 | 1552 | 79741270 |
| Blood parathyroid hormone increased | 25.56 | 21.43 | 7 | 1559 | 3438 | 79739384 |
| Tendon rupture | 23.95 | 21.43 | 9 | 1557 | 12117 | 79730705 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AA03 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Amino acids and derivatives |
| FDA CS | M0000922 | Amino Acids |
| FDA EPC | N0000175780 | Amino Acid |
| CHEBI has role | CHEBI:27027 | trace elements |
| CHEBI has role | CHEBI:50733 | Dietary Supplement |
| CHEBI has role | CHEBI:61908 | nitric oxide synthase inhibitors |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
| CHEBI has role | CHEBI:78675 | fundamental metabolites |
| CHEBI has role | CHEBI:25212 | metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Short bowel syndrome | indication | 26629001 | DOID:10605 |
| Hb SS disease | symptomatic treatment | 127040003 | DOID:10923 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.17 | acidic |
| pKa2 | 12.12 | acidic |
| pKa3 | 9.22 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 5GM/PACKET | ENDARI | EMMAUS MEDCL | N208587 | July 7, 2017 | RX | FOR SOLUTION | ORAL | July 7, 2024 | TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER. |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amino acid transporter | Transporter | IC50 | 4.57 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4027901 | VUID |
| N0000177918 | NUI |
| 4025874 | VANDF |
| 4027901 | VANDF |
| C0017797 | UMLSCUI |
| CHEBI:28300 | CHEBI |
| GLN | PDB_CHEM_ID |
| CHEMBL930 | ChEMBL_ID |
| DB00130 | DRUGBANK_ID |
| D005973 | MESH_DESCRIPTOR_UI |
| 5961 | PUBCHEM_CID |
| 1413 | INN_ID |
| 723 | IUPHAR_LIGAND_ID |
| 0RH81L854J | UNII |
| 4885 | RXNORM |
| 12067 | MMSL |
| 158599 | MMSL |
| 158601 | MMSL |
| d07315 | MMSL |
| 000928 | NDDF |
| 25761002 | SNOMEDCT_US |
| 412421007 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Endari | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42457-420 | POWDER, FOR SOLUTION | 5 g | ORAL | NDA | 26 sections |
| Endari | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42457-420 | POWDER, FOR SOLUTION | 5 g | ORAL | NDA | 26 sections |